Canakinumab in the treatment of systemic juvenile idiopathic arthritis: a retrospective single center study in China

Canakinumab in the treatment of systemic juvenile idiopathic arthritis: a retrospective single center study in China

ObjectiveSystemic juvenile idiopathic arthritis (sJIA) is characterized by excessive production of proinflammatory cytokines. As an anti-IL-1 agent, canakinumab has been approved in the USA and Europe for the treatment of sJIA patients aged ≥2 years. However, the use of canakinumab has never been re...

Full description

Bibliographic Details
Main Authors:	Xiaona Zhu, Ruohang Weng, Yanyan Huang, Yongbin Xu, Jun Yang, Tingyan He
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-03-01
Series:	Frontiers in Pediatrics
Subjects:	canakinumab interleukin-1 systemic juvenile idiopathic arthritis macrophage activation syndrome cytokine
Online Access:	https://www.frontiersin.org/articles/10.3389/fped.2024.1349907/full

Similar Items

Efficacy and safety of canakinumab in systemic juvenile idiopathic arthritis, the first Chinese experience
by: Lingzhi Qiu, et al.
Published: (2024-03-01)

Standard and increased canakinumab dosing to quiet macrophage activation syndrome in children with systemic juvenile idiopathic arthritis
by: Mikhail M. Kostik, et al.
Published: (2022-07-01)

Myositis in the course of the systemic form juvenile idiopathic arthritis
by: Piotr Gietka, et al.
Published: (2014-06-01)

Experiences with IL-1 blockade in systemic juvenile idiopathic arthritis – data from the German AID-registry
by: Elke Lainka, et al.
Published: (2021-03-01)

Efficacy and safety of canakinumab as a second line biologic after tocilizumab treatment failure in children with systemic juvenile idiopathic arthritis: A single-centre cohort study using routinely collected health data
by: Ekaterina Alexeeva, et al.
Published: (2023-02-01)

IL-1 inhibition in systemic juvenile idiopathic arthritis
by: Gabriella Giancane, et al.
Published: (2016-12-01)

Drug Retention Rate and Predictive Factors of Drug Survival for Interleukin-1 Inhibitors in Systemic Juvenile Idiopathic Arthritis
by: Jurgen Sota, et al.
Published: (2019-01-01)

The role of IL-1 inhibition in systemic juvenile idiopathic arthritis: current status and future perspectives
by: Toplak N, et al.
Published: (2018-06-01)

Kawasaki Disease and Systemic Juvenile Idiopathic Arthritis – Two Ends of the Same Spectrum
by: Ellen Go, et al.
Published: (2021-04-01)

Specific Features of Juvenile Idiopathic Arthritis Patients’ Cytokine Profile
by: Daria I. Kozlova, et al.
Published: (2024-01-01)

Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry
by: Gerd Horneff, et al.
Published: (2017-11-01)

Juvenile idiopathic arthritis with systemic onset with inflammatory bone lesions: two case reports of patients successfully treated with canakinumab and experience gained from literature
by: Ekaterina I. Alexeeva, et al.
Published: (2023-05-01)

Therapy with canakinumab for gout
by: M. S. Eliseev, et al.
Published: (2019-04-01)

Signals and Mechanisms Regulating Monocyte and Macrophage Activation in the Pathogenesis of Juvenile Idiopathic Arthritis
by: Chao-Yi Wu, et al.
Published: (2021-07-01)

The new Childhood Arthritis and Rheumatology Research Alliance (CARRA) registry: design, rationale, and characteristics of patients enrolled in the first 12 months
by: Timothy Beukelman, et al.
Published: (2017-04-01)

The Role of Interleukin-17 in Juvenile Idiopathic Arthritis: From Pathogenesis to Treatment
by: Marino Paroli, et al.
Published: (2022-10-01)

Fatal myocarditis in a child with systemic onset juvenile idiopathic arthritis during treatment with an interleukin 1 receptor antagonist
by: Zeft Andrew S, et al.
Published: (2012-04-01)

JAK inhibitors in systemic juvenile idiopathic arthritis
by: Tingyan He, et al.
Published: (2023-04-01)

An unusual presentation of purine nucleoside phosphorylase deficiency mimicking systemic juvenile idiopathic arthritis complicated by macrophage activation syndrome
by: Alessia Arduini, et al.
Published: (2019-05-01)

Tocilizumab for juvenile idiopathic arthritis: a single-center case series
by: Fatma Yazılıtaş, et al.
Published: (2020-03-01)

Original paper Predictors of juvenile idiopathic arthritis course
by: Jaryna J. Bojko, et al.
Published: (2015-08-01)

Macrophage activation syndrome in a patient with systemic onset of the juvenile idiopathic arthritis
by: Deepak Jain, et al.
Published: (2016-03-01)

Elbow monoarthritis: an atypical onset of juvenile idiopathic arthritis Elbow monoarthritis: an atypical juvenile idiopathic arthritis onset
by: G. Simonini, et al.
Published: (2012-07-01)

Juvenile idiopathic arthritis: from aetiopathogenesis to therapeutic approaches
by: Lina N. Zaripova, et al.
Published: (2021-08-01)

Juvenile idiopathic arthritis in Jordan: single center experience
by: Raed M. Alzyoud, et al.
Published: (2021-06-01)

Uveitis in patients with oligoarticular juvenile idiopathic arthritis and juvenile spondyloarthritis/enthesitis related arthritis: is there any difference?
by: A. Martins, et al.
Published: (2023-05-01)

IL-6 blockade in systemic juvenile idiopathic arthritis – achievement of inactive disease and remission (data from the German AID-registry)
by: M. Bielak, et al.
Published: (2018-04-01)

Vitamin D and juvenile idiopathic arthritis
by: Sarah L. Finch, et al.
Published: (2018-05-01)

Juvenile Idiopathic Arthritis and Exercise
by: Pınar Kısacık, et al.
Published: (2016-04-01)

Therapy with canakinumab for adult-onset still's disease
by: E. L. Nasonov
Published: (2019-04-01)

Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis
by: İlknur Tuğal-Tutkun
Published: (2016-04-01)

EXPERIENCE WITH ABATACEPT IN TREATMENT OF JUVENILE IDIOPATHIC ARTHRITIS
by: Margarita Fedorovna Dubko, et al.
Published: (2012-10-01)

Clinical manifestations of gastrointestinal tract changes in children with juvenile idiopathic arthritis
by: Natalia Shevchenko, et al.
Published: (2021-12-01)

Juvenile idiopathic arthritis – classification and methods of treatment
by: Weronika Pawłocik, et al.
Published: (2023-04-01)

Performance of interferon-gamma levels may lead to earlier diagnosing macrophage activation syndrome complicating systemic juvenile idiopathic arthritis
by: Meiping Lu, et al.
Published: (2023-10-01)

The necessity, efficacy and safety of biologics in juvenile idiopathic arthritis
by: Mustafa Cakan, et al.
Published: (2020-03-01)

Phenylketonuria and juvenile idiopathic arthritis: a case report
by: Ting Ting Zhu, et al.
Published: (2021-03-01)

Distribusi Subtipe Juvenile Idiopathic Arthritis di Bandung
by: Reni Ghrahani, et al.
Published: (2012-06-01)

Clinical variability of the systemic juvenile idiopathic arthritis course: literature review based on case series
by: Oksana Boyarchuk, et al.
Published: (2020-12-01)

Plasma level of myeloperoxidase in children with juvenile idiopathic arthritis (a pilot study)
by: Pruunsild Chris, et al.
Published: (2010-02-01)